2015
DOI: 10.3892/mco.2015.485
|View full text |Cite
|
Sign up to set email alerts
|

Circulating antibodies to p16 protein-derived peptides in breast cancer

Abstract: Abstract. Overexpression of the p16 protein has been reported in breast cancer and may trigger the secretion of antibodies against itself. Circulating anti-p16 antibodies that were detected with a recombinant protein have been reported in breast cancer. The present study was designed to determine whether the levels of circulating IgG antibody to p16 protein-derived linear antigens are altered in breast cancer. An enzyme-linked immunosorbent assay (ELISA) was developed in-house to determine circulating IgG agai… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
9
0

Year Published

2016
2016
2021
2021

Publication Types

Select...
7
2

Relationship

3
6

Authors

Journals

citations
Cited by 12 publications
(10 citation statements)
references
References 23 publications
1
9
0
Order By: Relevance
“…Circulating anti-CD25 IgG was detected with a modified ELISA method that was developed using a linear peptide antigen derived from human CD25 protein according to previous studies [13][14][15][16][17]; a control antigen was designed based on a maize protein (NCBI accession 1BFA_A), and its sequence is as follows:…”
Section: Autoantibody Testingmentioning
confidence: 99%
“…Circulating anti-CD25 IgG was detected with a modified ELISA method that was developed using a linear peptide antigen derived from human CD25 protein according to previous studies [13][14][15][16][17]; a control antigen was designed based on a maize protein (NCBI accession 1BFA_A), and its sequence is as follows:…”
Section: Autoantibody Testingmentioning
confidence: 99%
“…Natural autoantibodies are considered to be important antitumor systems in vivo,showing a decrease in earlystage cancer patients while a gradual increase during the tumor progresses [18,25]. A number of studies have been concerned about the role of natural autoantibodies in NSCLC, esophageal cancer, breast cancer and liver cancer, including those for p16, FOXP3, CD25, ABCC3, ANXA1, BIRC5, MYC and VEGFR1 [18,[25][26][27][28][29]. It has been supposed that natural autoantibodies may be useful anticancer agents for postoperative therapies to prevent the recurrence of human cancer.…”
Section: Discussionmentioning
confidence: 99%
“…Natural autoantibodies are considered to be important antitumor systems in vivo showing a decrease in early-stage cancer patients while a gradual increase during the tumor progresses [18,25]. A number of studies have been concerned about the role of natural autoantibodies in NSCLC, esophageal cancer, breast cancer and liver cancer, including those for p16, FOXP3, CD25, ABCC3, ANXA1, BIRC5, MYC and VEGFR1 [18,[25][26][27][28][29]. It has been supposed that natural autoantibodies may be useful anticancer agents for postoperative therapies to prevent the recurrence of human cancer.…”
Section: Discussionmentioning
confidence: 99%